Evidence map›Paper›PMID 32417688›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2020

Selective deficiency in endothelial PTP1B protects from diabetes and endoplasmic reticulum stress-associated endothelial dysfunction via preventing endothelial cell apoptosis.

Samuel Legeay, Pierre Fautrat, J Blake Norman, Galina Antonova, Simone Kennard, Thiago Bruder-Nascimento, Vijay S Patel, Sebastien Faure, Eric J Belin de Chantemèle

Open access · goldAbstract read
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Samuel LegeayMicro & Nanomédecines Translationelles-MINT, UNIV Angers, INSERM U1066, CNRS UMR 6021, UBL Université Bretagne Loire, Angers F-49933, France; Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Pierre FautratVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
J Blake NormanVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Galina AntonovaVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Simone KennardVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Thiago Bruder-NascimentoVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Vijay S PatelSection of Cardiothoracic Surgery, Department of Surgery, Medical College of Georgia, Augusta University, USA.
Sebastien FaureMicro & Nanomédecines Translationelles-MINT, UNIV Angers, INSERM U1066, CNRS UMR 6021, UBL Université Bretagne Loire, Angers F-49933, France.
Eric J Belin de ChantemèleVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Medicine (Cardiology), Medical College of Georgia, Augusta University, Augusta, GA, USA. Electronic address: ebelindechanteme@augusta.edu.
Augusta University · USCentre National de la Recherche Scientifique · FRInserm · FR

Funding

Leptin in HIV associated vascular diseasesR01HL147639 · NHLBI · AUGUSTA UNIVERSITY · PI BELIN DE CHANTEMELE, ERIC J · 2020 to 2023
$2.0M
Aldosterone Contribution to Leptin-mediated Hypertension in Obese FemalesR01HL130301 · NHLBI · AUGUSTA UNIVERSITY · PI BELIN DE CHANTEMELE, ERIC J · 2016 to 2020
$1.9M
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophiesK99HL140139 · NHLBI · AUGUSTA UNIVERSITY · PI BRUDER, THIAGO · 2018 to 2019
$231k
NHLBI NIH HHS K99 HL140139NHLBI NIH HHS R01 HL130301NHLBI NIH HHS R01 HL147639
6 · The paper itself

Abstract

Diabetes notably increases the risk for endothelial dysfunction, a main precursor for microvascular complications. While endoplasmic reticulum stress (ERS) and protein tyrosine phosphatase 1B (PTP1B) have been associated with endothelial dysfunction in resistance vessels, whether these mechanisms also contribute to diabetes-mediated endothelial dysfunction in conduit arteries remains unknown. Herein, we tested the hypothesis that diabetes induces macrovascular endothelial dysfunction via endothelial ERS-induced, PTP1B-mediated apoptosis. We showed that diabetes concomitantly increased the expression of PTP1B and of markers of ERS, including GRP78, XBP1, splXBP1 and CHOP in human vessels. Exposure of aortic rings from wild-type mice to the ERS inducers tunicamycin and thapsigargin markedly reduced endothelium-dependent relaxation. Global and endothelial-specific deletion of PTP1B as well as pharmacological inhibition protected aortic rings from ERS-mediated endothelial dysfunction. Nitric oxide synthase inhibition with l-NAME abolished relaxation in the presence and absence of ERS, but neither reactive oxygen species scavenging with tempol or peg-catalase, nor cyclooxygenase inhibition with indomethacin prevented ERS-mediated endothelial dysfunction. However, both p38-MAPK and JNK inhibition protected aortic rings from ERS-mediated endothelial dysfunction. In HUVECs, PTP1B deletion prevented ERS-induced PARP cleavage and apoptosis. Lastly, acute ERS inhibition in aortic rings and selective deficiency of endothelial PTP1B in mice protected mice from diabetes-induced endothelial dysfunction. Altogether, these data support the contribution of the p38/JNK-apoptosis pathway in ERS-mediated endothelial dysfunction and present endothelial PTP1B as a major regulator of endothelial cell viability in conduit vessels and a potential target for the management of macrovascular diseases in diabetes.

Indexed as

AnimalsApoptosisCell SurvivalDiabetes Mellitus, ExperimentalEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressEndothelial CellsHumansMaleMAP Kinase Signaling SystemMiceMice, Inbred BALB CMice, Inbred C57BLMice, Knockoutp38 Mitogen-Activated Protein KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 1Endoplasmic Reticulum Chaperone BiPHSPA5 protein, humanHspa5 protein, mousep38 Mitogen-Activated Protein KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 1PTPN1 protein, humanPtpn1 protein, mouseApoptosisDiabetesEndoplasmic reticulum stressEndothelial functionProtein tyrosine phosphatase 1B

Identifiers

PMID32417688
PMCPMC7685223
OpenAlexW3024574889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.